|

MRG003 Clinical Trials

3 actively recruiting trials

No change since May 2026

Pipeline

Phase 1: 1Phase 2: 2

Top Sponsors

  • Shanghai Miracogen Inc.1
  • Jiyan Liu1
  • Groupe Oncologie Radiotherapie Tete et Cou1

Indications

  • Cancer3
  • Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck1
  • Locally Advanced Head and Neck Squamous Cell Carcinoma1
  • Penile Cancer1

Other3 trials

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Phase 2
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
Phase 2
MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.